CN117940156A - 治疗性乳头瘤病毒疫苗 - Google Patents

治疗性乳头瘤病毒疫苗 Download PDF

Info

Publication number
CN117940156A
CN117940156A CN202280053653.9A CN202280053653A CN117940156A CN 117940156 A CN117940156 A CN 117940156A CN 202280053653 A CN202280053653 A CN 202280053653A CN 117940156 A CN117940156 A CN 117940156A
Authority
CN
China
Prior art keywords
nucleic acid
hpv
cells
cell
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280053653.9A
Other languages
English (en)
Chinese (zh)
Inventor
克里斯蒂安·蒂里翁
科杜拉·珀特尔
亚历山大·卡拉斯
沃尔克·桑迪格
英格·乔丹
彼得·乔纳斯·霍斯特
迪特·拉贝克·布伊勒森
拉夫·瓦格纳
帕特里克·奈克曼
贝内迪克·阿斯巴赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inprose Private LLC
Cirian Biotechnology Co ltd
ProBioGen AG
University of Regensburg
Original Assignee
Inprose Private LLC
Cirian Biotechnology Co ltd
ProBioGen AG
University of Regensburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inprose Private LLC, Cirian Biotechnology Co ltd, ProBioGen AG, University of Regensburg filed Critical Inprose Private LLC
Publication of CN117940156A publication Critical patent/CN117940156A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202280053653.9A 2021-08-18 2022-08-17 治疗性乳头瘤病毒疫苗 Pending CN117940156A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21191940.2 2021-08-18
EP21191940.2A EP4137153A1 (en) 2021-08-18 2021-08-18 Therapeutic papilloma virus vaccines
PCT/EP2022/073016 WO2023021116A1 (en) 2021-08-18 2022-08-17 Therapeutic papilloma virus vaccines

Publications (1)

Publication Number Publication Date
CN117940156A true CN117940156A (zh) 2024-04-26

Family

ID=77398487

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280053653.9A Pending CN117940156A (zh) 2021-08-18 2022-08-17 治疗性乳头瘤病毒疫苗

Country Status (9)

Country Link
US (1) US20250066427A1 (enExample)
EP (2) EP4137153A1 (enExample)
JP (1) JP2024532853A (enExample)
KR (1) KR20240095168A (enExample)
CN (1) CN117940156A (enExample)
AU (1) AU2022331111A1 (enExample)
CA (1) CA3229203A1 (enExample)
MX (1) MX2024002010A (enExample)
WO (1) WO2023021116A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119569831A (zh) * 2024-12-13 2025-03-07 深圳锦时生物科技有限公司 一种活性多肽及在预防和/或治疗hpv中的应用
WO2026149106A1 (zh) * 2025-01-10 2026-07-16 成都迈科康生物科技股份有限公司 一种rna疫苗及其相关产品

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026523389A (ja) * 2023-05-26 2026-07-14 プロバイオジェン アーゲー 二倍体組換え核細胞質大型ｄｎａウイルスベクター
CN120607593A (zh) * 2024-03-06 2025-09-09 诺未生物技术(无锡)有限公司 治疗hpv感染相关疾病的药物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
EP1427443A4 (en) * 2001-08-23 2006-03-08 Merck & Co Inc VACCINES WITH PAPILLOMA VIRUS E PROTEINS DELIVERED BY A VIRAL VECTOR
SI1957528T1 (sl) 2005-11-30 2013-02-28 University Of Copenhagen Nukleotidno cepivo
SI2865387T1 (sl) 2008-11-21 2019-10-30 Kobenhavns Univ University Of Copenhagen Primiranje imunskega odziva
GB201321384D0 (en) 2013-12-04 2014-01-15 Isis Innovation Molecular adjuvant
EP3452087A1 (en) * 2016-05-02 2019-03-13 Janssen Vaccines & Prevention B.V. Therapeutic hpv vaccine combinations
WO2018060288A1 (en) * 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
GB201704417D0 (en) 2017-03-20 2017-05-03 Univ Copenhagen Improved li vaccine adjuvant
US12576143B2 (en) 2018-10-19 2026-03-17 Nouscom Ag Teleost invariant chain cancer vaccine

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119569831A (zh) * 2024-12-13 2025-03-07 深圳锦时生物科技有限公司 一种活性多肽及在预防和/或治疗hpv中的应用
WO2026149106A1 (zh) * 2025-01-10 2026-07-16 成都迈科康生物科技股份有限公司 一种rna疫苗及其相关产品

Also Published As

Publication number Publication date
MX2024002010A (es) 2024-04-18
EP4387662A1 (en) 2024-06-26
EP4137153A1 (en) 2023-02-22
CA3229203A1 (en) 2023-02-23
AU2022331111A1 (en) 2024-03-07
WO2023021116A1 (en) 2023-02-23
US20250066427A1 (en) 2025-02-27
KR20240095168A (ko) 2024-06-25
JP2024532853A (ja) 2024-09-10

Similar Documents

Publication Publication Date Title
US20230086859A1 (en) Hpv vaccines
JP7735344B2 (ja) 疾患の予防および／または治療における使用のためのワクチン
US20250066427A1 (en) Therapeutic papilloma virus vaccines
JP6606571B2 (ja) 治療用ｈｐｖ１６ワクチン
He et al. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16
US20200123571A1 (en) Compositions and Methods of Treatment
JP2019068852A (ja) 治療用ｈｐｖ１８ワクチン
JP2020527029A (ja) Ｈｉｖ抗原をコードするポックスウイルスベクターおよびその使用方法
Boilesen et al. Efficacy and Synergy with Cisplatin of an Adenovirus Vectored Therapeutic E1E2E6E7 Vaccine against HPV Genome–Positive C3 Cancers in Mice
Neckermann et al. Design and immunological validation of macaca fascicularis papillomavirus type 3 based vaccine candidates in outbred mice: basis for future testing of a therapeutic papillomavirus vaccine in NHPs
US20250041399A1 (en) Cmv-based human papillomavirus vaccines
Neckermann Design and Characterization of Vaccine Candidates for Therapeutic Vaccination Against Papillomaviruses
Liao Studies of therapeutic vaccination and immune evasion by human papillomavirus oncoproteins
AU2015213420B2 (en) HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: Germany

Address after: German Grey Foer Finn

Applicant after: Ruiweidi Gene Transfer Co.,Ltd.

Applicant after: UNIVERSITAT REGENSBURG

Country or region after: Denmark

Applicant after: InProse Private LLC

Applicant after: PROBIOGEN AG

Address before: German Grey Foer Finn

Applicant before: Cirian Biotechnology Co.,Ltd.

Country or region before: Germany

Applicant before: UNIVERSITAT REGENSBURG

Applicant before: InProse Private LLC

Country or region before: Denmark

Applicant before: PROBIOGEN AG

CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: Germany

Address after: German Grey Foer Finn

Applicant after: Rui Fu Di Gene Delivery Limited Liability Company

Applicant after: UNIVERSITAT REGENSBURG

Country or region after: Denmark

Applicant after: InProse Private LLC

Applicant after: PROBIOGEN AG

Address before: German Grey Foer Finn

Applicant before: Ruiweidi Gene Transfer Co.,Ltd.

Country or region before: Germany

Applicant before: UNIVERSITAT REGENSBURG

Applicant before: InProse Private LLC

Country or region before: Denmark

Applicant before: PROBIOGEN AG